Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinxiang Qingjie Oral Liquid is a traditional Chinese medicine (TCM) developed by Guangzhou Yipinhong Pharmaceutical (also known as Apichope) for the treatment of pediatric influenza. Formulated as an oral liquid, it is specifically designed for children aged 0 to 14 years. The drug is recognized as a National Key Project in China and has received marketing approval. Its therapeutic approach is based on TCM principles of clearing heat and detoxifying, aimed at relieving symptoms associated with viral respiratory infections and internal heat. It is one of the core products in Yipinhong's pediatric portfolio and is noted for its role in addressing pediatric viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinxiang Qingjie Oral Liquid.